Dyadic International, Inc. (NASDAQ:DYAI) Short Interest Up 9.8% in September

Dyadic International, Inc. (NASDAQ:DYAI) was the recipient of a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 133,900 shares, an increase of 9.8% from the September 15th total of 122,000 shares. Currently, 0.7% of the company’s stock are short sold. Based on an average daily volume of 32,600 shares, the days-to-cover ratio is presently 4.1 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Dyadic International stock. Callan Capital LLC purchased a new position in Dyadic International, Inc. (NASDAQ:DYAI) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 27,174 shares of the biotechnology company’s stock, valued at approximately $45,000. Callan Capital LLC owned 0.09% of Dyadic International at the end of the most recent reporting period. Institutional investors own 27.95% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of Dyadic International in a research report on Monday, July 8th.

Dyadic International Stock Performance

Shares of NASDAQ:DYAI traded down $0.02 during mid-day trading on Thursday, reaching $1.14. 22,175 shares of the company traded hands, compared to its average volume of 50,747. The company’s 50 day moving average price is $1.23 and its 200-day moving average price is $1.50. The firm has a market cap of $33.33 million, a PE ratio of -4.07 and a beta of 0.73. The company has a debt-to-equity ratio of 1.72, a current ratio of 5.39 and a quick ratio of 5.39. Dyadic International has a 52 week low of $0.93 and a 52 week high of $2.67.

Dyadic International (NASDAQ:DYAI) last posted its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.01). Dyadic International had a negative return on equity of 145.95% and a negative net margin of 428.86%. The business had revenue of $0.39 million during the quarter, compared to the consensus estimate of $1.00 million. During the same quarter in the previous year, the company earned ($0.07) earnings per share. On average, equities analysts expect that Dyadic International will post -0.26 EPS for the current fiscal year.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.